BridgeMD
Compares treatment options for Overactive Bladder (OAB)
Official title Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
ClinicalTrials.gov ID: NCT07473310
What this study is testing
What is Oral Solifenacin succinate 5 mg?
Oral Solifenacin succinate 5 mg is an investigational medicine, given as an once-weekly pill taken by mouth, being studied as a potential treatment for overactive bladder (oab).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women. The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- OAB symptoms persisting for ≥3 months.
- OAB Symptom Score (OABSS) ≥7.
- Ability and willingness to provide informed consent
You likely can't join if
- Active urinary tract infection.
- Stress urinary incontinence as primary diagnosis.
- Pelvic organ prolapse stage ≥II.
- History of pelvic radiation or surgery within 6 months.
- Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout.
- Pregnancy or breast feeding.
See the full eligibility criteria
- OAB symptoms persisting for ≥3 months.
- OAB Symptom Score (OABSS) ≥7.
- Ability and willingness to provide informed consent
- Active urinary tract infection.
- Stress urinary incontinence as primary diagnosis.
- Pelvic organ prolapse stage ≥II.
- History of pelvic radiation or surgery within 6 months.
- Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout.
- Pregnancy or breast feeding.
- Neuropathic diseases or psychological disorders.
- History of urogenital malignancy.
- Uncontrolled DM (HbA1c \> 6.8)
- Uncorrected coagulopathy or severe cardiovascular disease.
- Contraindication to solifenacin e.g.: closed angle glaucoma)
The study team makes the final eligibility decision.
Where it's taking place
- Al Mansurah, Dakahlia Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Al Mansurah, Dakahlia Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.